February 7, 2014
NuvaRing Settlement Announced: Merck & Co. agrees to resolve thousands of potential claims
Plaintiffs lawyers representing thousands of women suing related to the birth control product NuvaRing® announced that a settlement was reached with Merck & Co. (MRK:US) on Feb. 7, 2014. Merck agreed to pay a lump sum of $100 million to resolve more than 1,800 potential product liability claims.
NuvaRing contains the hormones progestin and estrogen and has been available to women in the U.S. since 2001. Motley Rice began reviewing potential cases related to side effects such as blood clots, deep vein thrombosis, heart attack, stroke among other injuries in 2007.
Motley Rice member Carmen Scott serves on the Plaintiffs’ Steering Committee of the NuvaRing multidistrict litigation and represent clients in state and federal cases.
As Scott told Law360, “the settlement would resolve more than 1,800 lawsuits…the cases must first meet certain criteria to qualify for the settlement.”
Read more about Motley Rice’s prescription and over-the-counter drug practice which includes numerous other birth control products.
Read more about the NuvaRing settlement:
Feb. 7, 2014: Reuters – Merck to pay $100 million in NuvaRing contraceptive settlement
Feb. 7, 2014: BloombergBusinessweek – Merck to pay $100 million NuvaRing pact if enough women join